A Novel PI3K-driven Mouse Model of Intrahepatic Cholangiocarcinoma and Synergistic Antitumor Effects of Combined PI3K and WEE1 Inhibition

Hiromi Tsuchiya(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Yugo Ishino(Yokohama City University Medical Center), Makoto Sugimori(Yokohama City University Medical Center), Akito Nozaki(Yokohama City University Medical Center), Akihiro Funaoka(Yokohama City University Medical Center), Shotaro Tsunoda(Yokohama City University Medical Center), Yushi Kanemaru(Yokohama City University), Soichiro Sue(Yokohama City University), Sho Onodera(Yokohama City University), Ritsuko Oishi(Yokohama City University Medical Center), Yuichi Suzuki(Yokohama City University Medical Center), Takashi Kaneko(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Yoshimasa Suzuki(Yokohama City University Medical Center), Kazuki Endo(Yokohama City University Medical Center), Haruo Miwa(Yokohama City University Medical Center)
Research Square
June 12, 2026
10.21203/rs.3.rs-9508063/v1
Cited by 0

Related Papers

Analysis of apoptotic and antiapoptotic signalling pathways induced by <i>Helicobacter pylori</i>
|Gut|2002|93
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
|Journal of Gastroenterology|2017|91
Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib
|Liver Cancer|2019|91
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib
|Hepatology Research|2011|77
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
|BMC Cancer|2019|77